These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12679126)

  • 1. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
    Walenga JM; Jeske WP; Samama MM; Frapaise FX; Bick RL; Fareed J
    Expert Opin Investig Drugs; 2002 Mar; 11(3):397-407. PubMed ID: 11866668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
    Leone G; Rossi E; Leone AM; De Stefano V
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):311-26. PubMed ID: 15320782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
    Reynolds NA; Perry CM; Scott LJ
    Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin pentasaccharide.
    Gallus AS; Coghlan DW
    Curr Opin Hematol; 2002 Sep; 9(5):422-9. PubMed ID: 12172461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
    Bauer KA; Hawkins DW; Peters PC; Petitou M; Herbert JM; van Boeckel CA; Meuleman DG
    Cardiovasc Drug Rev; 2002; 20(1):37-52. PubMed ID: 12070533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.
    Walenga JM; Fareed J; Jeske WP; Bıck RL; Samama MM
    Turk J Haematol; 2002 Jun; 19(2):137-50. PubMed ID: 27264755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
    Bauer KA; Eriksson BI; Lassen MR; Turpie AG
    Curr Opin Pulm Med; 2002 Sep; 8(5):398-404. PubMed ID: 12172443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From heparins to factor Xa inhibitors and beyond.
    Alban S
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux, the first selective factor Xa inhibitor.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    Curr Opin Hematol; 2003 Sep; 10(5):327-32. PubMed ID: 12913785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism.
    Robinson DM; Wellington K
    Am J Cardiovasc Drugs; 2005; 5(5):335-46. PubMed ID: 16156690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring anticoagulation by fondaparinux: determination of anti factor Xa-level].
    Dämgen-von Brevern G; Kläffling C; Lindhoff-Last E
    Hamostaseologie; 2005 Aug; 25(3):281-5. PubMed ID: 16113752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemistry and clinical pharmacology of new anticoagulant agents.
    Samama MM; Gerotziafas GT; Elalamy I; Horellou MH; Conard J
    Pathophysiol Haemost Thromb; 2002; 32(5-6):218-24. PubMed ID: 13679646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.
    Nijkeuter M; Huisman MV
    Curr Opin Pulm Med; 2004 Sep; 10(5):338-44. PubMed ID: 15316429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.
    Raskob GE; Hirsh J
    Chest; 2003 Dec; 124(6 Suppl):379S-385S. PubMed ID: 14668421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.